Shots: The US approval is based on MOMENTUM 3 trial results enrolling 1000 patients with NYHA Class IIIB or IV heart failure for a short-term endpoint of six months and a long-term endpoint of two years The study demonstrated survival rate 82.8% @ 2yrs., clotting of blood 1.1% @ 2yrs., stroke rate of 10 % […]Read More
Tags : Advance Heart Failure
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US